http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 23 Jul 2026 07:11:31 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Arcus+Biosciences+%28RCUS%29/26804449.html <p>H.C. Wainwright analyst Emily Bodnar reiterated a Buy rating and $45.00 price target on Arcus Biosciences (NYSE: RCUS).</p><p>The analyst commented: "Cas' 2nd PD-(L)1/VEGF bsAb pairing further validates its emerging role as a TKI-sparing 1L backbone in ccRCC. Yesterday after market close, Arcus announced a clinical trial collaboration with Summit (SMMT; Neutral; Kapoor) to evaluate its HIF-2α inhibitor casdatifan (cas), in combination with ivonescimab (ivo; anti-PD-1/VEGF bispecific) in ccRCC, including 1L metastatic disease. The combo will be assessed in a new cohort within ARC-20, Arcus' platform study. Summit will supply ivo while Arcus conducts and sponsors the trial. Both companies will http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Arcus+Biosciences+%28RCUS%29/26804449.html Thu, 23 Jul 2026 07:11:31 -0400 RCUS http://www.streetinsider.com/Corporate+News/Arcus%2C+AVEO+to+test+kidney+cancer+drug+combo+in+new+trial/26802205.html <p>Arcus Biosciences (NYSE: RCUS) announced a clinical supply agreement with AVEO Oncology, an LG Chem company, to evaluate the combination of casdatifan and tivozanib in patients with advanced kidney cancer who previously received HIF-2α inhibitor therapy.</p> <p>Under the agreement, the two companies will add a new randomized cohort to Arcus's ARC-20 platform study, comparing casdatifan plus tivozanib (1.34 mg) against tivozanib alone in patients with advanced clear cell renal cell carcinoma (ccRCC). AVEO will supply tivozanib, while Arcus will conduct and sponsor the study. Each company retains development and commercial rights to its respective compounds. Enrollment is expected to begin in http://www.streetinsider.com/Corporate+News/Arcus%2C+AVEO+to+test+kidney+cancer+drug+combo+in+new+trial/26802205.html Wed, 22 Jul 2026 16:35:16 -0400 A.06822034 A.22847412 A.50100157 O.00823584 O.03960636 O.20026344 O.29486884 RCUS http://www.streetinsider.com/Corporate+News/Arcus%2C+AVEO+to+test+kidney+cancer+drug+combo+in+new+trial/26802205.html <p>Arcus Biosciences (NYSE: RCUS) announced a clinical supply agreement with AVEO Oncology, an LG Chem company, to evaluate the combination of casdatifan and tivozanib in patients with advanced kidney cancer who previously received HIF-2α inhibitor therapy.</p> <p>Under the agreement, the two companies will add a new randomized cohort to Arcus's ARC-20 platform study, comparing casdatifan plus tivozanib (1.34 mg) against tivozanib alone in patients with advanced clear cell renal cell carcinoma (ccRCC). AVEO will supply tivozanib, while Arcus will conduct and sponsor the study. Each company retains development and commercial rights to its respective compounds. Enrollment is expected to begin in http://www.streetinsider.com/Corporate+News/Arcus%2C+AVEO+to+test+kidney+cancer+drug+combo+in+new+trial/26802205.html Wed, 22 Jul 2026 16:35:16 -0400 A.06822034 A.22847412 A.50100157 O.00823584 O.03960636 O.20026344 O.29486884 RCUS http://www.streetinsider.com/Corporate+News/Arcus%2C+AVEO+to+test+kidney+cancer+drug+combo+in+new+trial/26802205.html <p>Arcus Biosciences (NYSE: RCUS) announced a clinical supply agreement with AVEO Oncology, an LG Chem company, to evaluate the combination of casdatifan and tivozanib in patients with advanced kidney cancer who previously received HIF-2α inhibitor therapy.</p> <p>Under the agreement, the two companies will add a new randomized cohort to Arcus's ARC-20 platform study, comparing casdatifan plus tivozanib (1.34 mg) against tivozanib alone in patients with advanced clear cell renal cell carcinoma (ccRCC). AVEO will supply tivozanib, while Arcus will conduct and sponsor the study. Each company retains development and commercial rights to its respective compounds. Enrollment is expected to begin in http://www.streetinsider.com/Corporate+News/Arcus%2C+AVEO+to+test+kidney+cancer+drug+combo+in+new+trial/26802205.html Wed, 22 Jul 2026 16:35:16 -0400 A.06822034 A.22847412 A.50100157 O.00823584 O.03960636 O.20026344 O.29486884 RCUS http://www.streetinsider.com/Corporate+News/Arcus%2C+AVEO+to+test+kidney+cancer+drug+combo+in+new+trial/26802205.html <p>Arcus Biosciences (NYSE: RCUS) announced a clinical supply agreement with AVEO Oncology, an LG Chem company, to evaluate the combination of casdatifan and tivozanib in patients with advanced kidney cancer who previously received HIF-2α inhibitor therapy.</p> <p>Under the agreement, the two companies will add a new randomized cohort to Arcus's ARC-20 platform study, comparing casdatifan plus tivozanib (1.34 mg) against tivozanib alone in patients with advanced clear cell renal cell carcinoma (ccRCC). AVEO will supply tivozanib, while Arcus will conduct and sponsor the study. Each company retains development and commercial rights to its respective compounds. Enrollment is expected to begin in http://www.streetinsider.com/Corporate+News/Arcus%2C+AVEO+to+test+kidney+cancer+drug+combo+in+new+trial/26802205.html Wed, 22 Jul 2026 16:35:16 -0400 A.06822034 A.22847412 A.50100157 O.00823584 O.03960636 O.20026344 O.29486884 RCUS http://www.streetinsider.com/Corporate+News/Arcus%2C+AVEO+to+test+kidney+cancer+drug+combo+in+new+trial/26802205.html <p>Arcus Biosciences (NYSE: RCUS) announced a clinical supply agreement with AVEO Oncology, an LG Chem company, to evaluate the combination of casdatifan and tivozanib in patients with advanced kidney cancer who previously received HIF-2α inhibitor therapy.</p> <p>Under the agreement, the two companies will add a new randomized cohort to Arcus's ARC-20 platform study, comparing casdatifan plus tivozanib (1.34 mg) against tivozanib alone in patients with advanced clear cell renal cell carcinoma (ccRCC). AVEO will supply tivozanib, while Arcus will conduct and sponsor the study. Each company retains development and commercial rights to its respective compounds. Enrollment is expected to begin in http://www.streetinsider.com/Corporate+News/Arcus%2C+AVEO+to+test+kidney+cancer+drug+combo+in+new+trial/26802205.html Wed, 22 Jul 2026 16:35:16 -0400 A.06822034 A.22847412 A.50100157 O.00823584 O.03960636 O.20026344 O.29486884 RCUS http://www.streetinsider.com/Corporate+News/Arcus%2C+AVEO+to+test+kidney+cancer+drug+combo+in+new+trial/26802205.html <p>Arcus Biosciences (NYSE: RCUS) announced a clinical supply agreement with AVEO Oncology, an LG Chem company, to evaluate the combination of casdatifan and tivozanib in patients with advanced kidney cancer who previously received HIF-2α inhibitor therapy.</p> <p>Under the agreement, the two companies will add a new randomized cohort to Arcus's ARC-20 platform study, comparing casdatifan plus tivozanib (1.34 mg) against tivozanib alone in patients with advanced clear cell renal cell carcinoma (ccRCC). AVEO will supply tivozanib, while Arcus will conduct and sponsor the study. Each company retains development and commercial rights to its respective compounds. Enrollment is expected to begin in http://www.streetinsider.com/Corporate+News/Arcus%2C+AVEO+to+test+kidney+cancer+drug+combo+in+new+trial/26802205.html Wed, 22 Jul 2026 16:35:16 -0400 A.06822034 A.22847412 A.50100157 O.00823584 O.03960636 O.20026344 O.29486884 RCUS http://www.streetinsider.com/Corporate+News/Arcus%2C+AVEO+to+test+kidney+cancer+drug+combo+in+new+trial/26802205.html <p>Arcus Biosciences (NYSE: RCUS) announced a clinical supply agreement with AVEO Oncology, an LG Chem company, to evaluate the combination of casdatifan and tivozanib in patients with advanced kidney cancer who previously received HIF-2α inhibitor therapy.</p> <p>Under the agreement, the two companies will add a new randomized cohort to Arcus's ARC-20 platform study, comparing casdatifan plus tivozanib (1.34 mg) against tivozanib alone in patients with advanced clear cell renal cell carcinoma (ccRCC). AVEO will supply tivozanib, while Arcus will conduct and sponsor the study. Each company retains development and commercial rights to its respective compounds. Enrollment is expected to begin in http://www.streetinsider.com/Corporate+News/Arcus%2C+AVEO+to+test+kidney+cancer+drug+combo+in+new+trial/26802205.html Wed, 22 Jul 2026 16:35:16 -0400 A.06822034 A.22847412 A.50100157 O.00823584 O.03960636 O.20026344 O.29486884 RCUS http://www.streetinsider.com/Corporate+News/Arcus%2C+AVEO+to+test+kidney+cancer+drug+combo+in+new+trial/26802205.html <p>Arcus Biosciences (NYSE: RCUS) announced a clinical supply agreement with AVEO Oncology, an LG Chem company, to evaluate the combination of casdatifan and tivozanib in patients with advanced kidney cancer who previously received HIF-2α inhibitor therapy.</p> <p>Under the agreement, the two companies will add a new randomized cohort to Arcus's ARC-20 platform study, comparing casdatifan plus tivozanib (1.34 mg) against tivozanib alone in patients with advanced clear cell renal cell carcinoma (ccRCC). AVEO will supply tivozanib, while Arcus will conduct and sponsor the study. Each company retains development and commercial rights to its respective compounds. Enrollment is expected to begin in http://www.streetinsider.com/Corporate+News/Arcus%2C+AVEO+to+test+kidney+cancer+drug+combo+in+new+trial/26802205.html Wed, 22 Jul 2026 16:35:16 -0400 A.06822034 A.22847412 A.50100157 O.00823584 O.03960636 O.20026344 O.29486884 RCUS http://www.streetinsider.com/Press+Releases/Arcus+Biosciences+Announces+Clinical+Supply+Agreement+with+AVEO+Oncology+to+Evaluate+Casdatifan+in+Combination+with+Tivozanib+for+Advanced+Kidney+Cancer+Patients/26802199.html <ul class="bwlistdisc"> <li> <i>This agreement supports a new randomized cohort within the ARC-20 study evaluating investigational casdatifan plus tivozanib versus tivozanib alone in patients who received prior HIF-2α-inhibitor therapy</i> </li> </ul><ul class="bwlistdisc"> <li> <i>Enrollment is expected to begin in the fourth quarter of 2026</i> </li> </ul> <p> HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced a clinical supply agreement with AVEO Oncology, an LG Chem company (“AVEO”). Under the agreement, the companies will evaluate casdatifan, Arcus’s investigational small-molecule HIF-2α inhibitor, in combination with http://www.streetinsider.com/Press+Releases/Arcus+Biosciences+Announces+Clinical+Supply+Agreement+with+AVEO+Oncology+to+Evaluate+Casdatifan+in+Combination+with+Tivozanib+for+Advanced+Kidney+Cancer+Patients/26802199.html Wed, 22 Jul 2026 16:35:00 -0400 A.06822034 A.22847412 A.50100157 O.00823584 O.03960636 O.20026344 O.29486884 RCUS http://www.streetinsider.com/Press+Releases/Arcus+Biosciences+Announces+Clinical+Supply+Agreement+with+AVEO+Oncology+to+Evaluate+Casdatifan+in+Combination+with+Tivozanib+for+Advanced+Kidney+Cancer+Patients/26802199.html <ul class="bwlistdisc"> <li> <i>This agreement supports a new randomized cohort within the ARC-20 study evaluating investigational casdatifan plus tivozanib versus tivozanib alone in patients who received prior HIF-2α-inhibitor therapy</i> </li> </ul><ul class="bwlistdisc"> <li> <i>Enrollment is expected to begin in the fourth quarter of 2026</i> </li> </ul> <p> HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced a clinical supply agreement with AVEO Oncology, an LG Chem company (“AVEO”). Under the agreement, the companies will evaluate casdatifan, Arcus’s investigational small-molecule HIF-2α inhibitor, in combination with http://www.streetinsider.com/Press+Releases/Arcus+Biosciences+Announces+Clinical+Supply+Agreement+with+AVEO+Oncology+to+Evaluate+Casdatifan+in+Combination+with+Tivozanib+for+Advanced+Kidney+Cancer+Patients/26802199.html Wed, 22 Jul 2026 16:35:00 -0400 A.06822034 A.22847412 A.50100157 O.00823584 O.03960636 O.20026344 O.29486884 RCUS http://www.streetinsider.com/Press+Releases/Arcus+Biosciences+Announces+Clinical+Supply+Agreement+with+AVEO+Oncology+to+Evaluate+Casdatifan+in+Combination+with+Tivozanib+for+Advanced+Kidney+Cancer+Patients/26802199.html <ul class="bwlistdisc"> <li> <i>This agreement supports a new randomized cohort within the ARC-20 study evaluating investigational casdatifan plus tivozanib versus tivozanib alone in patients who received prior HIF-2α-inhibitor therapy</i> </li> </ul><ul class="bwlistdisc"> <li> <i>Enrollment is expected to begin in the fourth quarter of 2026</i> </li> </ul> <p> HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced a clinical supply agreement with AVEO Oncology, an LG Chem company (“AVEO”). Under the agreement, the companies will evaluate casdatifan, Arcus’s investigational small-molecule HIF-2α inhibitor, in combination with http://www.streetinsider.com/Press+Releases/Arcus+Biosciences+Announces+Clinical+Supply+Agreement+with+AVEO+Oncology+to+Evaluate+Casdatifan+in+Combination+with+Tivozanib+for+Advanced+Kidney+Cancer+Patients/26802199.html Wed, 22 Jul 2026 16:35:00 -0400 A.06822034 A.22847412 A.50100157 O.00823584 O.03960636 O.20026344 O.29486884 RCUS http://www.streetinsider.com/Press+Releases/Arcus+Biosciences+Announces+Clinical+Supply+Agreement+with+AVEO+Oncology+to+Evaluate+Casdatifan+in+Combination+with+Tivozanib+for+Advanced+Kidney+Cancer+Patients/26802199.html <ul class="bwlistdisc"> <li> <i>This agreement supports a new randomized cohort within the ARC-20 study evaluating investigational casdatifan plus tivozanib versus tivozanib alone in patients who received prior HIF-2α-inhibitor therapy</i> </li> </ul><ul class="bwlistdisc"> <li> <i>Enrollment is expected to begin in the fourth quarter of 2026</i> </li> </ul> <p> HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced a clinical supply agreement with AVEO Oncology, an LG Chem company (“AVEO”). Under the agreement, the companies will evaluate casdatifan, Arcus’s investigational small-molecule HIF-2α inhibitor, in combination with http://www.streetinsider.com/Press+Releases/Arcus+Biosciences+Announces+Clinical+Supply+Agreement+with+AVEO+Oncology+to+Evaluate+Casdatifan+in+Combination+with+Tivozanib+for+Advanced+Kidney+Cancer+Patients/26802199.html Wed, 22 Jul 2026 16:35:00 -0400 A.06822034 A.22847412 A.50100157 O.00823584 O.03960636 O.20026344 O.29486884 RCUS http://www.streetinsider.com/Press+Releases/Arcus+Biosciences+Announces+Clinical+Supply+Agreement+with+AVEO+Oncology+to+Evaluate+Casdatifan+in+Combination+with+Tivozanib+for+Advanced+Kidney+Cancer+Patients/26802199.html <ul class="bwlistdisc"> <li> <i>This agreement supports a new randomized cohort within the ARC-20 study evaluating investigational casdatifan plus tivozanib versus tivozanib alone in patients who received prior HIF-2α-inhibitor therapy</i> </li> </ul><ul class="bwlistdisc"> <li> <i>Enrollment is expected to begin in the fourth quarter of 2026</i> </li> </ul> <p> HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced a clinical supply agreement with AVEO Oncology, an LG Chem company (“AVEO”). Under the agreement, the companies will evaluate casdatifan, Arcus’s investigational small-molecule HIF-2α inhibitor, in combination with http://www.streetinsider.com/Press+Releases/Arcus+Biosciences+Announces+Clinical+Supply+Agreement+with+AVEO+Oncology+to+Evaluate+Casdatifan+in+Combination+with+Tivozanib+for+Advanced+Kidney+Cancer+Patients/26802199.html Wed, 22 Jul 2026 16:35:00 -0400 A.06822034 A.22847412 A.50100157 O.00823584 O.03960636 O.20026344 O.29486884 RCUS http://www.streetinsider.com/Press+Releases/Arcus+Biosciences+Announces+Clinical+Supply+Agreement+with+AVEO+Oncology+to+Evaluate+Casdatifan+in+Combination+with+Tivozanib+for+Advanced+Kidney+Cancer+Patients/26802199.html <ul class="bwlistdisc"> <li> <i>This agreement supports a new randomized cohort within the ARC-20 study evaluating investigational casdatifan plus tivozanib versus tivozanib alone in patients who received prior HIF-2α-inhibitor therapy</i> </li> </ul><ul class="bwlistdisc"> <li> <i>Enrollment is expected to begin in the fourth quarter of 2026</i> </li> </ul> <p> HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced a clinical supply agreement with AVEO Oncology, an LG Chem company (“AVEO”). Under the agreement, the companies will evaluate casdatifan, Arcus’s investigational small-molecule HIF-2α inhibitor, in combination with http://www.streetinsider.com/Press+Releases/Arcus+Biosciences+Announces+Clinical+Supply+Agreement+with+AVEO+Oncology+to+Evaluate+Casdatifan+in+Combination+with+Tivozanib+for+Advanced+Kidney+Cancer+Patients/26802199.html Wed, 22 Jul 2026 16:35:00 -0400 A.06822034 A.22847412 A.50100157 O.00823584 O.03960636 O.20026344 O.29486884 RCUS http://www.streetinsider.com/Press+Releases/Arcus+Biosciences+Announces+Clinical+Supply+Agreement+with+AVEO+Oncology+to+Evaluate+Casdatifan+in+Combination+with+Tivozanib+for+Advanced+Kidney+Cancer+Patients/26802199.html <ul class="bwlistdisc"> <li> <i>This agreement supports a new randomized cohort within the ARC-20 study evaluating investigational casdatifan plus tivozanib versus tivozanib alone in patients who received prior HIF-2α-inhibitor therapy</i> </li> </ul><ul class="bwlistdisc"> <li> <i>Enrollment is expected to begin in the fourth quarter of 2026</i> </li> </ul> <p> HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced a clinical supply agreement with AVEO Oncology, an LG Chem company (“AVEO”). Under the agreement, the companies will evaluate casdatifan, Arcus’s investigational small-molecule HIF-2α inhibitor, in combination with http://www.streetinsider.com/Press+Releases/Arcus+Biosciences+Announces+Clinical+Supply+Agreement+with+AVEO+Oncology+to+Evaluate+Casdatifan+in+Combination+with+Tivozanib+for+Advanced+Kidney+Cancer+Patients/26802199.html Wed, 22 Jul 2026 16:35:00 -0400 A.06822034 A.22847412 A.50100157 O.00823584 O.03960636 O.20026344 O.29486884 RCUS http://www.streetinsider.com/Press+Releases/Arcus+Biosciences+Announces+Clinical+Supply+Agreement+with+AVEO+Oncology+to+Evaluate+Casdatifan+in+Combination+with+Tivozanib+for+Advanced+Kidney+Cancer+Patients/26802199.html <ul class="bwlistdisc"> <li> <i>This agreement supports a new randomized cohort within the ARC-20 study evaluating investigational casdatifan plus tivozanib versus tivozanib alone in patients who received prior HIF-2α-inhibitor therapy</i> </li> </ul><ul class="bwlistdisc"> <li> <i>Enrollment is expected to begin in the fourth quarter of 2026</i> </li> </ul> <p> HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced a clinical supply agreement with AVEO Oncology, an LG Chem company (“AVEO”). Under the agreement, the companies will evaluate casdatifan, Arcus’s investigational small-molecule HIF-2α inhibitor, in combination with http://www.streetinsider.com/Press+Releases/Arcus+Biosciences+Announces+Clinical+Supply+Agreement+with+AVEO+Oncology+to+Evaluate+Casdatifan+in+Combination+with+Tivozanib+for+Advanced+Kidney+Cancer+Patients/26802199.html Wed, 22 Jul 2026 16:35:00 -0400 A.06822034 A.22847412 A.50100157 O.00823584 O.03960636 O.20026344 O.29486884 RCUS http://www.streetinsider.com/Business+Wire/Arcus+Biosciences+Announces+Clinical+Supply+Agreement+with+AVEO+Oncology+to+Evaluate+Casdatifan+in+Combination+with+Tivozanib+for+Advanced+Kidney+Cancer+Patients/26802199.html <ul class="bwlistdisc"> <li> <i>This agreement supports a new randomized cohort within the ARC-20 study evaluating investigational casdatifan plus tivozanib versus tivozanib alone in patients who received prior HIF-2α-inhibitor therapy</i> </li> </ul><ul class="bwlistdisc"> <li> <i>Enrollment is expected to begin in the fourth quarter of 2026</i> </li> </ul> <p> HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced a clinical supply agreement with AVEO Oncology, an LG Chem company (“AVEO”). Under the agreement, the companies will evaluate casdatifan, Arcus’s investigational small-molecule HIF-2α inhibitor, in combination with http://www.streetinsider.com/Business+Wire/Arcus+Biosciences+Announces+Clinical+Supply+Agreement+with+AVEO+Oncology+to+Evaluate+Casdatifan+in+Combination+with+Tivozanib+for+Advanced+Kidney+Cancer+Patients/26802199.html Wed, 22 Jul 2026 16:35:00 -0400 A.06822034 A.22847412 A.50100157 O.00823584 O.03960636 O.20026344 O.29486884 RCUS http://www.streetinsider.com/Business+Wire/Arcus+Biosciences+Announces+Clinical+Supply+Agreement+with+AVEO+Oncology+to+Evaluate+Casdatifan+in+Combination+with+Tivozanib+for+Advanced+Kidney+Cancer+Patients/26802199.html <ul class="bwlistdisc"> <li> <i>This agreement supports a new randomized cohort within the ARC-20 study evaluating investigational casdatifan plus tivozanib versus tivozanib alone in patients who received prior HIF-2α-inhibitor therapy</i> </li> </ul><ul class="bwlistdisc"> <li> <i>Enrollment is expected to begin in the fourth quarter of 2026</i> </li> </ul> <p> HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced a clinical supply agreement with AVEO Oncology, an LG Chem company (“AVEO”). Under the agreement, the companies will evaluate casdatifan, Arcus’s investigational small-molecule HIF-2α inhibitor, in combination with http://www.streetinsider.com/Business+Wire/Arcus+Biosciences+Announces+Clinical+Supply+Agreement+with+AVEO+Oncology+to+Evaluate+Casdatifan+in+Combination+with+Tivozanib+for+Advanced+Kidney+Cancer+Patients/26802199.html Wed, 22 Jul 2026 16:35:00 -0400 A.06822034 A.22847412 A.50100157 O.00823584 O.03960636 O.20026344 O.29486884 RCUS http://www.streetinsider.com/Business+Wire/Arcus+Biosciences+Announces+Clinical+Supply+Agreement+with+AVEO+Oncology+to+Evaluate+Casdatifan+in+Combination+with+Tivozanib+for+Advanced+Kidney+Cancer+Patients/26802199.html <ul class="bwlistdisc"> <li> <i>This agreement supports a new randomized cohort within the ARC-20 study evaluating investigational casdatifan plus tivozanib versus tivozanib alone in patients who received prior HIF-2α-inhibitor therapy</i> </li> </ul><ul class="bwlistdisc"> <li> <i>Enrollment is expected to begin in the fourth quarter of 2026</i> </li> </ul> <p> HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced a clinical supply agreement with AVEO Oncology, an LG Chem company (“AVEO”). Under the agreement, the companies will evaluate casdatifan, Arcus’s investigational small-molecule HIF-2α inhibitor, in combination with http://www.streetinsider.com/Business+Wire/Arcus+Biosciences+Announces+Clinical+Supply+Agreement+with+AVEO+Oncology+to+Evaluate+Casdatifan+in+Combination+with+Tivozanib+for+Advanced+Kidney+Cancer+Patients/26802199.html Wed, 22 Jul 2026 16:35:00 -0400 A.06822034 A.22847412 A.50100157 O.00823584 O.03960636 O.20026344 O.29486884 RCUS http://www.streetinsider.com/Business+Wire/Arcus+Biosciences+Announces+Clinical+Supply+Agreement+with+AVEO+Oncology+to+Evaluate+Casdatifan+in+Combination+with+Tivozanib+for+Advanced+Kidney+Cancer+Patients/26802199.html <ul class="bwlistdisc"> <li> <i>This agreement supports a new randomized cohort within the ARC-20 study evaluating investigational casdatifan plus tivozanib versus tivozanib alone in patients who received prior HIF-2α-inhibitor therapy</i> </li> </ul><ul class="bwlistdisc"> <li> <i>Enrollment is expected to begin in the fourth quarter of 2026</i> </li> </ul> <p> HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced a clinical supply agreement with AVEO Oncology, an LG Chem company (“AVEO”). Under the agreement, the companies will evaluate casdatifan, Arcus’s investigational small-molecule HIF-2α inhibitor, in combination with http://www.streetinsider.com/Business+Wire/Arcus+Biosciences+Announces+Clinical+Supply+Agreement+with+AVEO+Oncology+to+Evaluate+Casdatifan+in+Combination+with+Tivozanib+for+Advanced+Kidney+Cancer+Patients/26802199.html Wed, 22 Jul 2026 16:35:00 -0400 A.06822034 A.22847412 A.50100157 O.00823584 O.03960636 O.20026344 O.29486884 RCUS http://www.streetinsider.com/Business+Wire/Arcus+Biosciences+Announces+Clinical+Supply+Agreement+with+AVEO+Oncology+to+Evaluate+Casdatifan+in+Combination+with+Tivozanib+for+Advanced+Kidney+Cancer+Patients/26802199.html <ul class="bwlistdisc"> <li> <i>This agreement supports a new randomized cohort within the ARC-20 study evaluating investigational casdatifan plus tivozanib versus tivozanib alone in patients who received prior HIF-2α-inhibitor therapy</i> </li> </ul><ul class="bwlistdisc"> <li> <i>Enrollment is expected to begin in the fourth quarter of 2026</i> </li> </ul> <p> HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced a clinical supply agreement with AVEO Oncology, an LG Chem company (“AVEO”). Under the agreement, the companies will evaluate casdatifan, Arcus’s investigational small-molecule HIF-2α inhibitor, in combination with http://www.streetinsider.com/Business+Wire/Arcus+Biosciences+Announces+Clinical+Supply+Agreement+with+AVEO+Oncology+to+Evaluate+Casdatifan+in+Combination+with+Tivozanib+for+Advanced+Kidney+Cancer+Patients/26802199.html Wed, 22 Jul 2026 16:35:00 -0400 A.06822034 A.22847412 A.50100157 O.00823584 O.03960636 O.20026344 O.29486884 RCUS http://www.streetinsider.com/Business+Wire/Arcus+Biosciences+Announces+Clinical+Supply+Agreement+with+AVEO+Oncology+to+Evaluate+Casdatifan+in+Combination+with+Tivozanib+for+Advanced+Kidney+Cancer+Patients/26802199.html <ul class="bwlistdisc"> <li> <i>This agreement supports a new randomized cohort within the ARC-20 study evaluating investigational casdatifan plus tivozanib versus tivozanib alone in patients who received prior HIF-2α-inhibitor therapy</i> </li> </ul><ul class="bwlistdisc"> <li> <i>Enrollment is expected to begin in the fourth quarter of 2026</i> </li> </ul> <p> HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced a clinical supply agreement with AVEO Oncology, an LG Chem company (“AVEO”). Under the agreement, the companies will evaluate casdatifan, Arcus’s investigational small-molecule HIF-2α inhibitor, in combination with http://www.streetinsider.com/Business+Wire/Arcus+Biosciences+Announces+Clinical+Supply+Agreement+with+AVEO+Oncology+to+Evaluate+Casdatifan+in+Combination+with+Tivozanib+for+Advanced+Kidney+Cancer+Patients/26802199.html Wed, 22 Jul 2026 16:35:00 -0400 A.06822034 A.22847412 A.50100157 O.00823584 O.03960636 O.20026344 O.29486884 RCUS http://www.streetinsider.com/Business+Wire/Arcus+Biosciences+Announces+Clinical+Supply+Agreement+with+AVEO+Oncology+to+Evaluate+Casdatifan+in+Combination+with+Tivozanib+for+Advanced+Kidney+Cancer+Patients/26802199.html <ul class="bwlistdisc"> <li> <i>This agreement supports a new randomized cohort within the ARC-20 study evaluating investigational casdatifan plus tivozanib versus tivozanib alone in patients who received prior HIF-2α-inhibitor therapy</i> </li> </ul><ul class="bwlistdisc"> <li> <i>Enrollment is expected to begin in the fourth quarter of 2026</i> </li> </ul> <p> HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced a clinical supply agreement with AVEO Oncology, an LG Chem company (“AVEO”). Under the agreement, the companies will evaluate casdatifan, Arcus’s investigational small-molecule HIF-2α inhibitor, in combination with http://www.streetinsider.com/Business+Wire/Arcus+Biosciences+Announces+Clinical+Supply+Agreement+with+AVEO+Oncology+to+Evaluate+Casdatifan+in+Combination+with+Tivozanib+for+Advanced+Kidney+Cancer+Patients/26802199.html Wed, 22 Jul 2026 16:35:00 -0400 A.06822034 A.22847412 A.50100157 O.00823584 O.03960636 O.20026344 O.29486884 RCUS http://www.streetinsider.com/Business+Wire/Arcus+Biosciences+Announces+Clinical+Supply+Agreement+with+AVEO+Oncology+to+Evaluate+Casdatifan+in+Combination+with+Tivozanib+for+Advanced+Kidney+Cancer+Patients/26802199.html <ul class="bwlistdisc"> <li> <i>This agreement supports a new randomized cohort within the ARC-20 study evaluating investigational casdatifan plus tivozanib versus tivozanib alone in patients who received prior HIF-2α-inhibitor therapy</i> </li> </ul><ul class="bwlistdisc"> <li> <i>Enrollment is expected to begin in the fourth quarter of 2026</i> </li> </ul> <p> HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced a clinical supply agreement with AVEO Oncology, an LG Chem company (“AVEO”). Under the agreement, the companies will evaluate casdatifan, Arcus’s investigational small-molecule HIF-2α inhibitor, in combination with http://www.streetinsider.com/Business+Wire/Arcus+Biosciences+Announces+Clinical+Supply+Agreement+with+AVEO+Oncology+to+Evaluate+Casdatifan+in+Combination+with+Tivozanib+for+Advanced+Kidney+Cancer+Patients/26802199.html Wed, 22 Jul 2026 16:35:00 -0400 A.06822034 A.22847412 A.50100157 O.00823584 O.03960636 O.20026344 O.29486884 RCUS